Management of autosomal dominant hypocalcemia type 1: Literature review and clinical practice recommendations
Journal of Endocrinological Investigation · 28.11.2024 · 48 (4) · 831-844
DOI: 10.1007/s40618-024-02496-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Endocrinological Investigation, online erschienen am 28.11.2024. Verfasst von Thomas De Coster und 3 weiteren Autor:innen. Beteiligte Einrichtung: General Internal Medicine, University Hospitals Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Hypoparathyroidism, Hypercalciuria, Hypocalcemia, Practice Guidelines as Topic. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Autosomal Dominant Hypocalcemia type 1 (ADH1), caused by gain-of-function variants in the calcium-sensing receptor (CASR), is characterized by a variable degree of hypocalcemia and hypercalciuria with inappropriately low PTH. The clinical spectrum is broad, ranging from being asymptomatic to presenting with severe clinical features of hypocalcemia and end-organ damage such as nephrolithiasis and intracerebral calcifications. Although the underlying pathophysiology is different, ADH1 patients are often managed as patients with ‘classical’ primary hypoparathyroidism, possibly leading to (exacerbation of) hypercalciuria. New treatments such as PTH analogues and calcilytics directly targeting the CASR are in the pipeline. Specific clinical guidance for treatment and monitoring of ADH1 patients is lacking. The purpose of this study is to provide a literature review on management of ADH1, including new therapies, and to formulate practice recommendations.
Methods
We searched for articles and ongoing clinical trials regarding management of ADH1.
Results
Forty articles were included. First we review the conventional treatment of ADH1, focusing on active vitamin D, calcium supplements, thiazide diuretics, phosphorus binders and dietary recommendations. In a second part we give an overview of studies with emerging treatments in ADH1: PTH analogues (PTH1-34, rhPTH1-84, TransCon PTH and others) and calcilytics (preclinical studies and clinical trials). In a third part we discuss literature findings regarding monitoring of ADH1 patients. Finally, we formulate clinical practice recommendations.
Conclusion
We provide an overview of conventional and new treatments for ADH1 patients. Based on these data, we propose practical recommendations to assist clinicians in the management of ADH1 patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Internal Medicine, University Hospitals Leuven, Leuven, Belgium.
- Endocrinology, University Hospitals Leuven, Leuven, Herestraat 49, 3000, Belgium.
- Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium.
- Endocrinology, University Hospitals Leuven, Leuven, Herestraat 49, 3000, Belgium. brigitte.decallonne@uzleuven.be.
Zitieren
APA
De Coster, T., David, K., Breckpot, J., & Decallonne, B. (2024). Management of autosomal dominant hypocalcemia type 1: Literature review and clinical practice recommendations. Journal of Endocrinological Investigation, 48(4), 831-844. https://doi.org/10.1007/s40618-024-02496-y
Vancouver
De Coster T, David K, Breckpot J, Decallonne B. Management of autosomal dominant hypocalcemia type 1: Literature review and clinical practice recommendations. Journal of Endocrinological Investigation. 2024;48(4):831-844. doi:10.1007/s40618-024-02496-y
BibTeX
@article{DeCoster2024,
author = {De Coster, Thomas and David, Karel and Breckpot, Jeroen and Decallonne, Brigitte},
title = {Management of autosomal dominant hypocalcemia type 1: Literature review and clinical practice recommendations},
journal = {Journal of Endocrinological Investigation},
year = {2024},
volume = {48},
number = {4},
pages = {831--844},
doi = {10.1007/s40618-024-02496-y}
}
EUVIMED